

FIG. 1

DWVIPPINLPENSRGPFQQLVRI	SDRDKNLSLRYSVTGPGADQPPTGIFI	INP	mNC
DWVIPPISCPENEKGEFPKNLVQIKSNRDKETKVFYSITGQGADKPPVGVFIER			mEC
DWIWNQMHIDEKNTESPHHVGVKIKSSVSRK-NAKYLLKGEYVGK----	VERVDA		hVEC
<u>DWIWNQMHIDEKNE</u> SLPHYV- <u>KDQSNVNRQ-NAKYVLQGEFAGK----</u>	IFGVDA		mVEC
Peptide 1	Peptide 2	Peptide 3	
ISGQLSVTKPLDRELIA	RHRAH	AVDIN-GNQVENPIDIVINVIDMNDNRPEF	mNC
ETGWLKVTQPLDREAI	AKYILYSH	AVSSN-GEAVEDPMEIVITVTDQNDNRPEF	mEC
<b>ETGDVFA</b> IERLDRENISEYHLTA	VI	VDKDTGENLETPSSFTIKVHDVNDNWPVE	hVEC
NTGNVLA	YERLDREKVSEYFLTA	<u>IVDKNTNKNLEQPS</u> STVKVHDINDNWPVF	MVEC
		Peptide 4	

FIG. 2




FIG. 3




FIG. 4

**Effect of anti-VE-cadherin mAb 19E6 on  
b-FGF-induced neovascularization in  
mouse corneal micropocket assay**



Rat IgG1

19E6

FIG 5A




FIG. 5B

10010128 041001




FIG. 6




FIG. 7






FIG. 8

**DWIWNQMHI DEEKNESLPHYVKDQSNVNRQNAKYVLQGEFAGKIFGVDAN**  
**E4B9 19E6, 10G4 (Cad5)**

TGNVLAYERLDREKVSEYFLTALIVDKNTNKNLEQPSSFTVKVHDINDNWPVF

Murine ECD1

FIG. 9